Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Jan 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better manage the immune system of patients who have received a specific type of stem cell transplant called haploidentical allo-HSCT. The researchers want to see if regular health check-ups and reminders for follow-up visits can help improve the health and recovery of patients who have a high risk of immune-related issues after their transplant.

To participate, patients need to be at least 16 years old and must agree to take part in the study by signing a consent form. However, individuals who have undergone multiple transplants, have certain mental or medical conditions that could make it hard for them to follow the study requirements, or have other health concerns that might put them at risk are not eligible. If you qualify and decide to join, you can expect regular monitoring of your health and guidance to help support your recovery after the transplant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Patients must be ≥ 16 years of age;
• • 2) Patients receiving haploidentical allo-HSCT;
• • 3) Patients have to sign an informed consent form before the start of the research procedure.
• Exclusion Criteria:
• • 1) Tandem transplantation or multiple transplantations;
• • 2) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
• • 3) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.